Tuesday, June 23, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 946 of 1,261

  1. US 8053416

    Isolation and structure of turbostatins 1-4

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Nov 8, 2011 · Expires Nov 3, 2031

    granted

  2. US 8053443

    N-substituted indenoisoquinolines and syntheses thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Nov 8, 2011 · Expires Nov 3, 2031

    granted

  3. US 8053412

    NELL-1 peptides

    The Regents of the University of California · Granted Nov 8, 2011 · Expires Nov 3, 2031

    granted

  4. US 8052970

    Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 8, 2011 · Expires Nov 3, 2031

    granted

  5. US 8053434

    Kinase inhibitors and their uses

    Rigel Pharmaceuticals, Inc. · Granted Nov 8, 2011 · Expires Nov 3, 2031

    granted

  6. US 8053424

    Composition and method of treating hearing loss

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 8, 2011 · Expires Nov 3, 2031

    granted

  7. US 8048432

    Polysaccharide-protein conjugate vaccines

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  8. US 8048909

    Proton pump inhibitors

    Takeda Pharmaceutical Company Limited · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  9. US 8048427

    Subgenomic replicons of the flavivirus dengue

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  10. US 8048844

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  11. US 8048889

    3,4-disubstituted coumarin and quinolone compounds

    XTL BIOPHARMACEUTICALS LTD. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  12. US 8048415

    Compositions and methods for promoting or inhibiting angiogenesis

    Northwestern University · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  13. US 8048851

    Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

    The Regents of the University of California · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  14. US 8048906

    Optically pure and enriched isomers of chelating ligands and contrast agents

    Catalyst Medical · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  15. US 8048646

    NELL peptide expression systems and bone formation activity of NELL peptide

    The Regents of the University of California · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  16. US 8048990

    Modified vitamin K-dependent polypeptides

    Regents of the University of Minnesota · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  17. US 8049016

    Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes

    Xenon Pharmaceuticals Inc. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  18. US 8048222

    Highly pure modafinil

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  19. US 8048418

    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  20. US 8048902

    Antagonists of lysophosphatidic acid receptors

    AMIRA PHARMACEUTICALS, INC. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  21. US 8049015

    Heteroaryl antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  22. US 8044018

    Reagents and methods for smooth muscle therapies

    THE ARIZONA BOARD OF REGENTS · Granted Oct 25, 2011 · Expires Oct 20, 2031

    granted

  23. US 8044033

    Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Oct 25, 2011 · Expires Oct 20, 2031

    granted

  24. US 8043625

    Purified plasmodium and vaccine compositions

    Sanaria Inc. · Granted Oct 25, 2011 · Expires Oct 20, 2031

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.